Facebook Twitter Linkedin NASDAQ Market NewsClick here to email authorNEXT STORYNovartis Piqray® data show survival benefit for patients with HR+/HER2- advanced breast cancer with a PIK3CA mutationPREV STORYPhase 3 NORA data of ZEJULA® (niraparib) demonstrate significant PFS benefit, regardless of biomarker status, with an improved safety profile when given with individualized starting dose regimen in Chinese women with platinum-sensitive recurrent ovarian cancer